StockNews.com Initiates Coverage on OpGen (NASDAQ:OPGN)

Equities researchers at StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN) in a research note issued on Saturday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Price Performance

Shares of OPGN stock opened at $0.75 on Friday. The company’s fifty day simple moving average is $1.33 and its two-hundred day simple moving average is $1.95. OpGen has a 1 year low of $0.53 and a 1 year high of $9.90.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.